Chemical dimerizers and three-hybrid systems: scanning the proteome for targets of organic small molecules.
The integration of technological advances in areas as diverse as chemical biology, proteomics, genomics, automation, and bioinformatics has led to the emergence of novel screening paradigms for analyzing the molecular basis of drug action. This review summarizes recent advances in three-hybrid technologies and their application to the characterization of small molecule-protein interactions and proteome-wide identification of drug receptors.
Kley
Nikolai
N
GPC Biotech Inc., 610 Lincoln Street, Waltham, MA 02451 USA. nikolai.kley@gpc-biotech.com
D000818:Animals; D004268:DNA-Binding Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D019281:Dimerization; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D015870:Gene Expression; D040081:Protein Array Analysis; D020543:Proteome / Q000737:chemistry* / Q000235:genetics; D011955:Receptors, Drug / Q000032:analysis*; D015398:Signal Transduction; D020123:Sirolimus / Q000494:pharmacology; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D020798:Two-Hybrid System Techniques / Q000295:instrumentation
C119717:AP 1510; D004268:DNA-Binding Proteins; D020543:Proteome; D011955:Receptors, Drug; D020123:Sirolimus; D016559:Tacrolimus